Journal: ACS Nano

Article Title: Synergistic Viro-chemoimmunotherapy in Breast Cancer Enabled by Bioengineered Immunostimulatory Exosomes and Dual-Targeted Coxsackievirus B3

doi: 10.1021/acsnano.3c09491

Figure Lengend Snippet: Further modification of ExomiR-CVB3 with the AS1411 aptamer and doxorubicin enhances its specificity and cytotoxic potential. (A) Western blot analysis of nucleolin in RAW 264.7 macrophages, 4T1, and SUM149 breast cancer cells. (B) Agarose gel evaluation of the formation of ExomiR-CVB3/Apt through EDC–NHS coupling. The AS1411 Apt (10 μM) was activated by EDC/NHS and subsequently added to increasing concentrations of Exo-miR-CVB3 as indicated. After a 2 h incubation at room temperature, agarose gel electrophoresis was performed. (C) Schematic illustration of the assembly process of ExomiR-CVB3/DoxAp. (D) Confocal images of 4T1 cells incubated with different formulations as indicated ( n = 3 for each group). Scale bars = 50 μm. (E) Flow cytometry results of 4T1 cells treated with different formulations ( n = 3–5 for each group). (F) MTS viability assay of 4T1 cells treated with different formulations as indicated for 24 h. * p < 0.05, ** p < 0.01, *** p < 0.005, and **** p < 0.001 by ANOVA.

Article Snippet: The 4T1 cells (CRL-2539, a murine triple-negative mammary tumor cell line isolated from Balb/c mice), RAW 264.7 cells (TIB-71, a macrophage-like cell line derived from Balb/c mice), MDA-MB-231 (HTB-26) and SUM149 (CRL-2316) (human triple negative mammary tumor cell lines), HeLa cells (CCL-2, human cervical cancer cells), and MCF-7 cells (HTB-22, luminal A mammary tumor cell line) were obtained from the American Type Culture Collection.

Techniques: Modification, Western Blot, Agarose Gel Electrophoresis, Incubation, Flow Cytometry, Viability Assay

Journal: Veterinary Sciences

Article Title: Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines

doi: 10.3390/vetsci8090194

Figure Lengend Snippet: Tumor growth parameters of IPC-366 and SUM149 cell lines in ectopic and orthotopic models.

Article Snippet: The human triple-negative inflammatory breast cancer cell line SUM149 was obtained from Asterand, Inc. (Detroit, MI, USA), (RRID: CVCL_3422).

Techniques: Injection

Journal: Veterinary Sciences

Article Title: Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines

doi: 10.3390/vetsci8090194

Figure Lengend Snippet: IPC-366 and SUM149 xenotransplanted mice, paraffin sections, H-E. ( A ) IPC-366 ectopic xenotransplanted mice. Neoplastic cells arranged in solid masses separated by a scant fibrovascular stroma infiltrating the adjacent dermis (inset: neoplastic cells infiltrating adjacent dermis). ( B ) IPC-366 orthotopic mice. Unencapsulated and densely cellular mass extending into the adjacent adipose tissue. ( C , D ) Ectopic and orthotopic IPC-366 xenotransplanted mice. Tumors are composed of highly pleomorphic cells with marked anisocytosis and anisokaryosis. Binucleated cells are commonly seen (arrow). ( E , F ) Ectopic and orthotopic SUM149 xenografted mice. Solid tumors infiltrate the dermis and adipose tissue. No histological differences were found between the types of SUM149 xenografts. ( G ) Orthotopic SUM149 xenograft. Medium to large round cells with a moderate eosinophilic cytoplasm and large nuclei with one or more evident nucleoli. ( H ) Orthotopic SUM149 xenograft. Presence of neoplastic cells with an elongated and empty cytoplasm that displaced the nuclei to the periphery, suggestive of endothelial-like cells (ELCs) (arrow). Atypical mitoses were frequently seen (arrowhead).

Article Snippet: The human triple-negative inflammatory breast cancer cell line SUM149 was obtained from Asterand, Inc. (Detroit, MI, USA), (RRID: CVCL_3422).

Techniques:

Journal: Veterinary Sciences

Article Title: Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines

doi: 10.3390/vetsci8090194

Figure Lengend Snippet: Estrogen receptor (ER), Progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression on ectopic and orthotopic xenografts from IPC-366 and SUM149 cell lines.

Article Snippet: The human triple-negative inflammatory breast cancer cell line SUM149 was obtained from Asterand, Inc. (Detroit, MI, USA), (RRID: CVCL_3422).

Techniques: Expressing

Journal: Veterinary Sciences

Article Title: Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines

doi: 10.3390/vetsci8090194

Figure Lengend Snippet: Steroid hormone secretion studied (P4, DHEA, A4, T, DHT, E1SO4, and E2), on ectopic (subcutaneous) and orthotopic (mammary fat pad) models of IPC-366 and SUM149 xenografts.

Article Snippet: The human triple-negative inflammatory breast cancer cell line SUM149 was obtained from Asterand, Inc. (Detroit, MI, USA), (RRID: CVCL_3422).

Techniques:

Journal: Carcinogenesis

Article Title: Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells

doi: 10.1093/carcin/bgx003

Figure Lengend Snippet: EGFR-ERK signaling is necessary for BPA’s proliferative effect. (A) SUM149 cells treated for 24 h with either vehicle, BPA (40 nM), EGFR inhibitor GW583340 (2.5 μM), or EGFRi + BPA co-treatment and assessed for proliferation by MTT. Inset: western immunoblot analysis of SUM149 cells treated for 24 h with BPA (40 nM), EGFRi (2.5 μM) and probed for pEGFR and EGFR, with GAPDH used as a loading control. (B) rSUM149 were treated for 24 h with BPA at the indicated concentrations and assessed for proliferation by MTT. Inset: western immunoblot analysis of rSUM149 cells treated for 24 h with BPA (10 μM) and probed for pEGFR and EGFR, with GAPDH used as a loading control. (C) SUM190 cells were treated for 24 h with BPA at the indicated concentrations and assessed for proliferation by MTT. Inset: western immunoblot analysis of SUM190 cells treated for 24 h with EGFR/HER2i (GW583340; 7.5 μM), BPA (1 nM) or the combination and probed for pHER2 and HER2, with GAPDH used as a loading control. For each cell line study, proliferation data represents mean ± SD percent normalized to untreated control for a minimum of three independent assays, each carried out in triplicate. Statistical significance was calculated by the Student’s t-test. *P < 0.05, # P < 0.005, ns = not significant. For all western blots, numbers represent fold change of phospho proteins to total proteins and total proteins to GAPDH, normalized to untreated.

Article Snippet: The SUM149 (EGFR activated, triple negative) and SUM190 (HER2 overexpressing, ER/PR negative) IBC lines were obtained from Asterand, Inc. (Detroit, MI), derived from primary tumors of untreated IBC patients and cultured per manufacturer’s instructions as described previously ( 13 ).

Techniques: Western Blot, Control